Previous close | 29.83 |
Open | 30.00 |
Bid | 0.00 x 3000 |
Ask | 0.00 x 3000 |
Day's range | 29.73 - 30.14 |
52-week range | 25.20 - 34.11 |
Volume | |
Avg. volume | 31,613,395 |
Market cap | 168.584B |
Beta (5Y monthly) | 0.62 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.46 |
Earnings date | 29 Oct 2024 |
Forward dividend & yield | 1.68 (5.65%) |
Ex-dividend date | 26 July 2024 |
1y target est | 33.38 |
MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated EGFR-mutated NSCLC.
Senior health reporter Anjalee Khemlani joins Brad Smith and Madison Mills on Catalysts to take a look at pharmaceutical stocks like Novartis (NVS) and Novo Nordisk (NVO) as weight loss drug makers are set to meet with lawmakers like Senator Bernie Sanders to discuss pricing. Khemlani provides insight into the weight loss drug market and pricing in the US compared to other countries around the world. She explains that Pfizer (PFE), Eli Lilly (LLY), and Novo are among the candidates who could offer weight loss drugs in pill form rather than through injection, which could transform the market. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Naomi Buchanan.
We recently compiled a list of the 7 Best Stocks to Buy for Passive Income. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other good stocks to buy for passive income. With rising costs in today’s world, people are constantly searching for ways to earn additional […]